Andexxa
E852344
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
antidote
ⓘ
biologic drug ⓘ coagulation factor ⓘ drug ⓘ recombinant protein ⓘ reversal agent ⓘ |
| hasAdverseEffect |
infusion-related reactions
ⓘ
myocardial infarction ⓘ pneumonia ⓘ stroke ⓘ thromboembolism ⓘ urinary tract infection ⓘ |
| hasApprovalYear | 2018 ⓘ |
| hasATCCode | B02BD08 ⓘ |
| hasBlackBoxWarning |
cardiac arrest
ⓘ
ischemic events ⓘ sudden death ⓘ thromboembolic events ⓘ |
| hasContraindication | known hypersensitivity to andexanet alfa ⓘ |
| hasDosageForm |
intravenous injection
ⓘ
lyophilized powder for solution ⓘ |
| hasDrugClass |
factor Xa inhibitor reversal agent
ⓘ
hemostatic agent ⓘ |
| hasGenericName | andexanet alfa NERFINISHED ⓘ |
| hasINN | andexanet alfa NERFINISHED ⓘ |
| hasManufacturer |
Alexion Pharmaceuticals
NERFINISHED
ⓘ
Portola Pharmaceuticals NERFINISHED ⓘ |
| hasMechanismOfAction |
binds factor Xa inhibitors
ⓘ
restores factor Xa activity ⓘ sequesters direct factor Xa inhibitors ⓘ |
| hasNonproprietaryName | andexanet alfa NERFINISHED ⓘ |
| hasPharmacologicTarget |
apixaban
ⓘ
edoxaban NERFINISHED ⓘ enoxaparin ⓘ factor Xa inhibitors ⓘ rivaroxaban NERFINISHED ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| isAdministeredAs | intravenous bolus followed by infusion ⓘ |
| isApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| isIndicatedFor |
life-threatening bleeding
ⓘ
major bleeding associated with factor Xa inhibitors ⓘ reversal of anticoagulation ⓘ uncontrolled bleeding ⓘ |
| isModifiedFormOf | human factor Xa protein ⓘ |
| isRecombinantFormOf | human factor Xa ⓘ |
| isUsedToReverse |
apixaban
ⓘ
edoxaban NERFINISHED ⓘ enoxaparin ⓘ rivaroxaban ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.